Literature DB >> 18520771

Alzheimer disease pathology as a host response.

Rudy J Castellani1, Hyoung-Gon Lee, Xiongwei Zhu, George Perry, Mark A Smith.   

Abstract

Identification of amyloid-beta and tau as the major protein components of senile plaques and neurofibrillary tangles, respectively, led to an exponential increase in investigations of these proteins and their corresponding metabolic pathways in Alzheimer disease (AD). The presumptions inherent in most studies and in the dogma of the amyloid cascade concept are that these hallmark lesions in AD brains contain molecules that drive the disease process, and that the proteinaceous accumulations are themselves toxic. On the other hand, the lesions of AD are, by definition, end-stage, and their relationship to the clinical disease is inconsistent; this has long been known but, generally, has not been acknowledged until relatively recently. Some recent attempts to address the etiology and pathogenesis of AD discard the pathology and focus on the interplay between invisible toxic intermediates, that is, amyloid-beta oligomers and the synapse. The concept that the hallmark lesions may be nontoxic (something we have long suggested) is slowly gaining acceptance. We favor the interpretation that senile plaques and neurofibrillary tangles represent a host response to an upstream pathophysiologic process, and that the therapeutic targeting of lesions, including toxic intermediates, will succeed only in the event that the host response is directly deleterious. Therefore, renewed efforts aimed at elucidating fundamental age-related processes such as oxidative stress and/or inflammatory mediators are warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18520771      PMCID: PMC2763411          DOI: 10.1097/NEN.0b013e318177eaf4

Source DB:  PubMed          Journal:  J Neuropathol Exp Neurol        ISSN: 0022-3069            Impact factor:   3.685


  75 in total

1.  Mean age-of-onset of familial alzheimer disease caused by presenilin mutations correlates with both increased Abeta42 and decreased Abeta40.

Authors:  Samir Kumar-Singh; Jessie Theuns; Bianca Van Broeck; Daniel Pirici; Krist'l Vennekens; Ellen Corsmit; Marc Cruts; Bart Dermaut; Rong Wang; Christine Van Broeckhoven
Journal:  Hum Mutat       Date:  2006-07       Impact factor: 4.878

2.  Amyloid-beta vaccination: testing the amyloid hypothesis?: heads we win, tails you lose!

Authors:  Hyoung-gon Lee; Xiongwei Zhu; Akihiko Nunomura; George Perry; Mark A Smith
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

3.  Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease.

Authors:  J Steven Jacobsen; Chi-Cheng Wu; Jeffrey M Redwine; Thomas A Comery; Robert Arias; Mark Bowlby; Robert Martone; John H Morrison; Menelas N Pangalos; Peter H Reinhart; Floyd E Bloom
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-20       Impact factor: 11.205

4.  A specific amyloid-beta protein assembly in the brain impairs memory.

Authors:  Sylvain Lesné; Ming Teng Koh; Linda Kotilinek; Rakez Kayed; Charles G Glabe; Austin Yang; Michela Gallagher; Karen H Ashe
Journal:  Nature       Date:  2006-03-16       Impact factor: 49.962

5.  Reversal of Alzheimer's-like pathology and behavior in human APP transgenic mice by mutation of Asp664.

Authors:  Veronica Galvan; Olivia F Gorostiza; Surita Banwait; Marina Ataie; Anna V Logvinova; Sandhya Sitaraman; Elaine Carlson; Sarah A Sagi; Nathalie Chevallier; Kunlin Jin; David A Greenberg; Dale E Bredesen
Journal:  Proc Natl Acad Sci U S A       Date:  2006-04-25       Impact factor: 11.205

Review 6.  Involvement of oxidative stress in Alzheimer disease.

Authors:  Akihiko Nunomura; Rudy J Castellani; Xiongwei Zhu; Paula I Moreira; George Perry; Mark A Smith
Journal:  J Neuropathol Exp Neurol       Date:  2006-07       Impact factor: 3.685

7.  Argyrophilic grain disease in demented subjects presenting initially with amnestic mild cognitive impairment.

Authors:  Gregory A Jicha; Ronald C Petersen; David S Knopman; Bradley F Boeve; Glenn E Smith; Yonas E Geda; Kris A Johnson; Ruth Cha; Michael W Delucia; Heiko Braak; Dennis W Dickson; Joseph E Parisi
Journal:  J Neuropathol Exp Neurol       Date:  2006-06       Impact factor: 3.685

Review 8.  Are presenilins intramembrane-cleaving proteases? Implications for the molecular mechanism of Alzheimer's disease.

Authors:  M S Wolfe; J De Los Angeles; D D Miller; W Xia; D J Selkoe
Journal:  Biochemistry       Date:  1999-08-31       Impact factor: 3.162

Review 9.  Neuropathology of Alzheimer disease: pathognomonic but not pathogenic.

Authors:  Rudy J Castellani; Hyoung-Gon Lee; Xiongwei Zhu; Akihiko Nunomura; George Perry; Mark A Smith
Journal:  Acta Neuropathol       Date:  2006-04-27       Impact factor: 17.088

10.  The roles of cyclin-dependent kinase 5 and glycogen synthase kinase 3 in tau hyperphosphorylation.

Authors:  Florian Plattner; Marco Angelo; K Peter Giese
Journal:  J Biol Chem       Date:  2006-06-27       Impact factor: 5.157

View more
  55 in total

1.  Widespread distribution of reticulon-3 in various neurodegenerative diseases.

Authors:  Jonathon E Heath; Sandra L Siedlak; Xiongwei Zhu; Hyoung-Gon Lee; Akanksha Thakur; Riqiang Yan; George Perry; Mark A Smith; Rudy J Castellani
Journal:  Neuropathology       Date:  2010-12       Impact factor: 1.906

2.  Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease.

Authors:  Joseph L Price; Daniel W McKeel; Virginia D Buckles; Catherine M Roe; Chengjie Xiong; Michael Grundman; Lawrence A Hansen; Ronald C Petersen; Joseph E Parisi; Dennis W Dickson; Charles D Smith; Daron G Davis; Frederick A Schmitt; William R Markesbery; Jeffrey Kaye; Roger Kurlan; Christine Hulette; Brenda F Kurland; Roger Higdon; Walter Kukull; John C Morris
Journal:  Neurobiol Aging       Date:  2009-04-18       Impact factor: 4.673

Review 3.  The end of Alzheimer's disease--from biochemical pharmacology to ecopsychosociology: a personal perspective.

Authors:  Peter J Whitehouse
Journal:  Biochem Pharmacol       Date:  2013-12-01       Impact factor: 5.858

Review 4.  Murine models of Alzheimer's disease and their use in developing immunotherapies.

Authors:  Thomas Wisniewski; Einar M Sigurdsson
Journal:  Biochim Biophys Acta       Date:  2010-05-13

5.  Activity-dependent neuroprotective protein (ADNP) expression in the amyloid precursor protein/presenilin 1 mouse model of Alzheimer's disease.

Authors:  Rafael Fernandez-Montesinos; Manuel Torres; David Baglietto-Vargas; Antonia Gutierrez; Illana Gozes; Javier Vitorica; David Pozo
Journal:  J Mol Neurosci       Date:  2009-10-21       Impact factor: 3.444

6.  Abnormal post-translational and extracellular processing of brevican in plaque-bearing mice over-expressing APPsw.

Authors:  Joanne M Ajmo; Lauren A Bailey; Matthew D Howell; Lisa K Cortez; Keith R Pennypacker; Hina N Mehta; Dave Morgan; Marcia N Gordon; Paul E Gottschall
Journal:  J Neurochem       Date:  2010-02-17       Impact factor: 5.372

7.  Chronic traumatic encephalopathy: A paradigm in search of evidence?

Authors:  Rudy J Castellani
Journal:  Lab Invest       Date:  2015-04-13       Impact factor: 5.662

Review 8.  Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models.

Authors:  Thomas Wisniewski; Allal Boutajangout
Journal:  Brain Struct Funct       Date:  2009-12-10       Impact factor: 3.270

Review 9.  Amyloid-beta immunisation for Alzheimer's disease.

Authors:  Thomas Wisniewski; Uwe Konietzko
Journal:  Lancet Neurol       Date:  2008-07-28       Impact factor: 44.182

10.  Ectopic localization of FOXO3a protein in Lewy bodies in Lewy body dementia and Parkinson's disease.

Authors:  Bo Su; Haihua Liu; Xinglong Wang; Shu G Chen; Sandra L Siedlak; Eisaku Kondo; Raymond Choi; Atsushi Takeda; Rudy J Castellani; George Perry; Mark A Smith; Xiongwei Zhu; Hyoung-Gon Lee
Journal:  Mol Neurodegener       Date:  2009-07-23       Impact factor: 14.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.